|Traded as||NASDAQ: BIIB
S&P 500 Component
|Headquarters||Cambridge, Massachusetts, U.S.|
|Key people||Stelios Papadopoulos, Chairman, George A. Scangos, CEO|
|Products||Tecfidera, Avonex, Tysabri, Fampyra, Rituxan*, Gazyva*|
|Revenue||$695B in 2013|
|Employees||Approximately 7,000 (as of January 2014)|
Biogen Idec, Inc. is a global biotechnology company based in Cambridge, Massachusetts, specializing in discovering, developing, and delivering important therapies for the treatment of neurodegenerative, hematologic and autoimmune diseases to patients worldwide.
Biogen was founded in 1978 in Geneva by several prominent biologists, including Sir Kenneth Murray of the University of Edinburgh, Phillip Sharp of the Massachusetts Institute of Technology, Walter Gilbert of Harvard (who served as CEO during the start-up phase) and Charles Weissmann, University of Zurich (who contributed the first product interferon-alpha). Walter Gilbert and Phillip Sharp were both subsequently honored with a Nobel Prize: Gilbert was recognized in 1980 with Nobel Prize in Chemistry for his work in understanding the sequencing of DNA, while Sharp received the Nobel Prize in Medicine in 1993 for his discovery of split genes.
Biogen Idec stock is a component of several stock indices such as the S&P 100, S&P 500, S&P 1500, and NASDAQ-100 and the company is listed on the NASDAQ stock exchange under the ticker symbol, BIIB.
Biogen Idec is managed by an executive group composed of ten officers:
- George A. Scangos, Ph.D., Chief Executive Officer and Member, Board of Directors
- Susan H. Alexander, Executive Vice President, General Counsel and Corporate Secretary
- Spyros Artavanis-Tsakonas, Ph.D., Chief Scientific Officer
- Paul J. Clancy, Executive Vice President and Chief Financial Officer
- John G. Cox, Executive Vice President of Pharmaceutical Operations & Technology
- Kenneth DiPietro, Executive Vice President of Human Resources
- Steven H. Holtzman, Executive Vice President of Corporate Development
- Tony Kingsley, Executive Vice President of Global Commercial Operations
- Adam Koppel, Chief Strategy Office and Senior Vice President of Commercial Assessment and Disease Strategy
- Alfred W. Sandrock, Jr., M.D., Ph.D., Chief Medical Officer and Group Senior Vice President of Development Sciences
- Douglas E. Williams, Ph.D., Executive Vice President, Research and Development
As is customary for a publicly traded company, Biogen Idec is also overseen by a board of directors. The Executive Chairman and Chief Executive Officer both hold positions on the board of directors. The directors are Stelios Papadopoulos (chairman), George A. Scangos Ph.D. (CEO), Alexander J. Denner, Ph.D., Caroline Dorsa, Nancy L. Leaming, Richard C. Mulligan, Robert W. Pangia, Brian S. Posner, Eric K. Rowinsky, M.D., The Honorable Lynn Schenk, and Stephen A. Sherwin, M.D.
|Therapy||Indication (In United States unless otherwise noted)||Year Approved (US)||Year Approved (EU)||Additional Information!|
|ALPROLIX™ [Coagulation Factor IX (Recombinant), Fc Fusion Protein]||Control and prevention of bleeding episodes, perioperative management and routine prophylaxis in adults and children with hemophilia B||2014||Also approved in Canada and Australia.
Biogen Idec and Swedish Orphan Biovitrum (Sobi) are collaborators in the development and commercialization of ALPROLIX. 
|AVONEX® (interferon beta-1a)||Relapsing forms of multiple sclerosis||1996||1997||Includes the AVONEX PEN auto-injector and the AVOSTARTGRIP titration kit approved in the U.S. in 2012.|
|ELOCTATE™ [Antihemophilic Factor (Recombinant), Fc Fusion Protein]||Control and prevention of bleeding episodes, perioperative (surgical) management and routine prophylaxis in adults and children with hemophilia A||2014||Biogen Idec and Swedish Orphan Biovitrum (Sobi) are collaborators in the development and commercialization of ELOCTATE.|
|FAMPYRA® (prolonged-release fampridine tablets)||Multiple sclerosis (Walking ability)||2010||2011||Marketed by Biogen Idec in markets outside of the United Sates.
Commercialized in the United States as AMPYRA (dalfampridine) Extended Release Tablets, by Acorda Therapeutics.
|FUMADERM™ (fumaric acid esters)||Psoriasis||1994 (Germany only)||Approved in Germany.
Acquired in acquisition of Fumapharm AG in 2006.
|GAZYVA® (obinutuzumab)||Chronic lymphocytic leukemia||2013||The first medicine approved with the FDA’s Breakthrough Therapy Designation and is also currently in Phase 3 trials for NHL and diffuse large B-cell lymphoma.
Currently commercialized in the United States by Genentech, a wholly owned subsidiary of Roche. 
|RITUXAN® (rituximab)||Non-Hodgkin's Lymphoma (NHL)
Anti-TNF Refractory Rheumatoid Arthritis
|1998 (as MabThera)||The first monoclonal antibody for cancer developed by IDEC, prior to merging with Biogen.
Currently commercialized by Roche and its subsidiary, Genentech.
|TECFIDERA® (dimethyl fumarate)||Relapsing forms of multiple sclerosis||2013||2014|
|TYSABRI® (natalizumab)||Relapsing-remitting multiple sclerosis||2004 Re-introduced in 2006||2006||See below – Natalizumab withdrawal and re-introduction
Full rights purchased from partner Elan in 2013.
Biogen Idec has focused its R&D efforts on the discovery and development of treatments for patients with high unmet medical needs in the areas of neurology, hematology and immunology.
Investigational MS medicines:
- PLEGRIDY™ (peginterferon beta-1a): an investigational candidate for relapsing forms of MS. Pegylation of interferon beta-1a is believed to extend its half-life and prolong its exposure in the body. Biogen Idec filed BLAs for marking approval with the FDA and EMA in 2013 
- Daclizumab High-Yield Process (DAC HYP): is being developed as a potential once-monthly subcutaneous injection in the treatment of RRMS. DAC HYP is being developed in collaboration with Abbvie, Inc. In June 2014, the companies announced positive top-line results from the Phase III DECIDE clinical trial, where DAC HYP demonstrated superiority over interferon beta-1a in annualized relapse rate. 
- Anti-LINGO-1 (BIIB033): is the first candidate being investigated for its potential to remylinate and repair neurons damaged by MS, currently in Phase 2 trials.
Biogen Idec has several candidates in Phase 1 and 2 clinical trials in neurodegenerative and immunological diseases including MS, Alzheimer’s disease, neuropathic pain, spinal muscular atrophy and lupus nephritis:
- Phase 2a: anti-LINGO-1 molecule in acute optic neuritis
- Phase 2b: anti-TWEAK monoclonal antibody in lupus nephritis
- Phase 2a: STX-100 in patients with idiopathic pulmonary fibrosis
- Phase 2: neublastin for neuropathic pain in 2013
- Phase 2: ISIS-SMNRx for spinal muscular atrophy in infants and children in collaboration with Isis Pharmaceuticals
- Phase 1b: BIIB037, Biogen Idec’s first clinical study in Alzheimer’s disease
Biogen Idec also has several development agreements in place with Isis Pharmaceuticals to collaborate to leverage antisense technology in advancing the treatment of neurological disorders. 
In February 2012, Biogen Idec formalized a joint venture with Samsung, creating Samsung Bioepis. This joint venture brings Biogen Idec’s expertise and capabilities in protein engineering, cell line development, and recombinant biologics manufacturing to position the joint venture so Biogen Idec can participate in the emerging market for biosimilars.
In early 2014, Biogen Idec entered into an agreement with Eisai, Inc., to jointly develop and commercialize two of their candidates for Alzheimer’s disease, which have the potential to reduce Aβ plaques that form in the brains of patients, as well as to slow the formation of new plaques, potentially improving symptoms and suppressing disease progression.
- "Biotech's Comeback Kid". Forbes. Retrieved 2012-12-04.
- "Idec to Merge With Biogen in $6.8 Billion Deal". New York Times. Retrieved 2003-24-06.
- "Biogen Idec Inc. Stock Quote & Summary Data". NASDAQ. Retrieved unknown.
- "Biogen Idec Inc (BIIB) Top Compensated Officers". Business Week. Retrieved 2014-14-04.
- "Biogen Idec (BIIB) Chairman Young to Retire". StreetInsider.com. Retrieved 2014-18-02.
- "Does Biogen Idec Inc Have a New Blockbuster Hemophilia Therapy?". The Motley Fool. Retrieved 2014-07-04.
- "Avonex". National MS Society. Retrieved unknown.
- "Biogen Idec’s Eloctate gains FDA approval". The Pharma Letter. Retrieved 2014-09-06.
- "Fampridine (Fampyra)". MS Trust. Retrieved unknown.
- "Biogen Idec enters deal to acquire Fumapharm". First Word Pharma. Retrieved 2006-31-05.
- "FDA approves Gazyva for chronic lymphocytic leukemia". FDA.gov. Retrieved 2013-01-11.
- "FDA Approval for Rituximab". National Cancer Institute. Retrieved unknown.
- "UPDATE 1-Roche, Biogen end dispute over Rituxan follow-ons". Reuters. Retrieved 2010-21-10.
- "FDA approves Rituxan to treat two rare disorders". FDA.gov. Retrieved 2011-19-04.
- "Cell Therapeutics buys Zevalin from Biogen Idec for $10M, with up to $20M extra plus milestones". The Pharma Letter. Retrieved 2007-09-03.
- "Tecifedra". National MS Society. Retrieved unknown.
- "Tysabri". National MS Society. Retrieved unknown.
- "Excellent Results For MS Drug "Plegridy"". Medical News Today. Retrieved 2013-21-03.
- "Once-monthly MS drug from Biogen Idec, AbbVie clears Phase III hurdle". Fierce Biotech. Retrieved 2013-04-08.
- "Lingo: a promising remyelination target in MS". Multiple Sclerosis Research. Retrieved 2014-16-06.
- "Isis Pharmaceuticals and Biogen Idec". Fierce Biotech. Retrieved unknown.
- "Biogen Sees Eloctate FDA Delay Pushing Marketing to Mid-2014". BusinessWeek. Retrieved 2013-12-11.
- "Isis Pharmaceuticals and Biogen Idec". Fierce Biotech.